In the
September 21st issue of Science Translational Medicine (link), scientists at Genentech
reveal their findings about a new, clinically qualified biomarker of
non-response to antibody therapy to CD20 in rheumatoid arthritis (RA). B cell depleting therapy using the anti-CD20
mAb rituximab in RA (link) is reserved for patients who
have failed standard disease-modifying antirheumatic drugs (specifically
methotrexate) and/or with inadequate response to anti-TNF antibody
therapy. Considering the cost,
complexity, and relative risk associates with anti-CD20 therapy and considering
that about 50% of RA patients do not respond to rituximab, there is a strong
impetus to target this therapy to patients who are most likely to respond
favorably.
Hypothesizing
that RA patients with high frequency of antibody producing plasma B cells are
less likely to respond to rituximab (plasma cells do not express CD20), the
team at Genentech surveyed a set of B cell and plasma cell specific RNA
transcripts in blood samples from a subgroup of patients who had been treated
with rituximab (REFLEX study). Using the American College of Rheumatology
50% improvement criteria (ACR50), they identified a clear association between
failure to meet ACR50 and elevated levels of RNA for the immunoglobulin J chain
(IgJ) at baseline. They confirmed this observation using blood
samples from patients enrolled in two additional independent rituximab studies
(DANCER and SERENE), and one study of ocrelizumab
(a second generation anti-CD20 mAb) in RA (SCRIPT). When all four trials were combined, the ACR50
response rate in the active arms was 28% for the IgJlo group (n =
471) and 12% for the IgJhi group (n = 122) (Odd ratio: 2.7; 95%
confidence interval: 1.5 to 5.3). The
predictive power of the IgJ RNA level was further refined by combining this
parameter with the RNA levels for the B cell specific splice variant of Fc
Receptor-like 5 (FCRL5). Together, elevated levels of IgJ RNA and low
levels of FCRL5 at baseline (biomarker positive: IgJlo / FCRL5hi)
were strongly associated with low probability of positive response to anti-CD20
mAbs therapy (figure 1). Indeed, in the
combined 4 clinical studies, 28% of biomarker-negative patients responded to
treatment while only 9% of biomarker positive patients responded under the same
conditions (Odd ratio: 3.6; 95% confidence interval: 1.8 to 8.4). Of note, this combination biomarker does not
appear to be an indicator of more severe diseases since it was not associated
with different response rate in the placebo groups from those clinical studies.
Fig. 1
Beyond
representing a major advance in the area of treatment decision in RA
patients, this work represents a remarkable example of the power of well-planned, well-executed prospective
retrospective studies for the discovery and clinical qualification of novel
biomarkers
Thierry
Sornasse for Integrated Biomarker Strategy
No comments:
Post a Comment